Nebenwirkungen · Simponi
Simponi 50 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 39
HOS-121081 · Präparat HOS-095257
In the controlled period of pivotal trials, infections were observed in 23.0% of golimumab-treated patients (incidence per 100 subject-years: 132.0; 95% CI: 123.3, 141.1) compared with 20.2% of control patients (incidence per 100 subject-years: 122.3; 95% CI: 109.5, 136.2). In controlled and uncontrolled portions of the trials with a median follow-up of approximately 4 years, the incidence per 100 subject-years of infections was 81.1 events; 95% CI: 79.5, 82.8 for golimumab treated patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-30T15:08:00Z · SHA-256 9c07aa0af39af47a872fdf98b4749f232dd8d93a2e23d0c5c99feea1d99b8bfd · Passage 6e1ebe18c60aafcbbd67ff20cdf9229a32e3bf552bf2bfacaa826375c6ac94d3 · Zeichen 7926–8422 im Abschnitt